An early-biomarker algorithm predicts lethal graft-versus-host disease and survival

JCI Insight

Volumn 2, Issue 3, 2017, Pages

  Hartwell, Matthew J ^a   Özbek, Umut ^a   Holler, Ernst ^b   Renteria, Anne S ^a   Major Monfried, Hannah ^a   Reddy, Pavan ^c   Aziz, Mina ^a   Hogan, William J ^d   Ayuk, Francis ^e   Efebera, Yvonne A ^f   Hexner, Elizabeth O ^g   Bunworasate, Udomsak ^h   Qayed, Muna ⁱ   Ordemann, Rainer ^j   Wölfl, Matthias ^k   Mielke, Stephan ^k   Pawarode, Attaphol ^c   Chen, Yi Bin ^l   Devine, Steven ^f   Harris, Andrew C ^m   Jagasia, Madan ⁿ   Kitko, Carrie L ⁿ   Litzow, Mark R ^d   Kröger, Nicolaus ^e   Locatelli, Franco ^o   Morales, George ^a   Nakamura, Ryotaro ^p   Reshef, Ran ^q   Rösler, Wolf ^r   Weber, Daniela ^b   Wudhikarn, Kitsada ^h   Yanik, Gregory A ^c   Levine, John E ^a   Ferrara, James L M ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF MICHIGAN   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^o BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^p CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^q Department of Medicine   (United States)

^r UNIVERSITY HOSPITAL ERLANGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055135693     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/JCI.INSIGHT.89798     Document Type: Article

References (36)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.
2. Anasetti C, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
3. Gooley TA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-2101.
4. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S146-S151.
5. Harris AC, Ferrara JL, Levine JE. Advances in predicting acute GVHD. Br J Haematol. 2013;160(3):288-302.
6. Jagasia M, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296-307.
7. Finke J, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
8. Nucci M, et al. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transpl Infect Dis. 2003;5(4):167-173.
9. Tomblyn M, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
10. Majhail NS, et al. Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era. Biol Blood Marrow Transplant. 2015;21(1):142-150.
11. Levine JE, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2(1):e21-e29.
12. MacMillan ML, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21(4):761-767.
13. Kollman C, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127(2):260-267.
14. Castilla-Llorente C, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(7):966-971.
15. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204-3213.
16. Ferrara JL, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-6708.
17. Reichenbach DK, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015;125(20):3183-3192.
18. Zhang J, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med. 2015;7(308):308ra160.
19. Ueha S, et al. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects. J Leukoc Biol. 2007;81(1):176-185.
20. Waldman E, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006;107(4):1703-1711.
21. Murai M, et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol. 2003;4(2):154-160.
22. Chen YB, et al. Up-regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(9):1066-1076.
23. Targan SR, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672-1683.
24. Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-721.
25. Vermeire S, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309-318.
26. Ogawa H, et al. Increased expression of HIP/PAP and regenerating gene III in human inflammatory bowel disease and a murine bacterial reconstitution model. Inflamm Bowel Dis. 2003;9(3):162-170.
27. Levine JE, et al. Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood. 2013;122(8):1505-1509.
28. Munneke JM, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood. 2014;124(5):812-821.
29. + innate lymphoid cells. Immunology. 2011;132(4):453-465.
30. Lindemans CA, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature. 2015;528(7583):560-564.
31. Harris AC, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4-10.
32. Vander Lugt MT, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.
33. Paczesny S, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113(2):273-278.
34. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
35. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716-723.
36. Xu Q-S, Liang Y-Z. Monte Carlo cross validation. Chemometr Intell Lab. 2001;56(1):1-11.